Inhibitory effect of low-dose paclitaxel combined with recombinant human endostatin on breast cancer MCF-7 cell line

RAO Ming-yue; ZHANG Xing-ping; CHENG Li; ZHOU Tao-qi; YANG Min; HE Yang-ke

您当前的位置：

首页 >

文章列表页 >

Inhibitory effect of low-dose paclitaxel combined with recombinant human endostatin on breast cancer MCF-7 cell line

更新时间：2024-01-17

- Inhibitory effect of low-dose paclitaxel combined with recombinant human endostatin on breast cancer MCF-7 cell line
- Journal of Chongqing Medical University Vol. 36, Issue 11, Pages: 1335-1338(2011)
- 作者机构：
  
  重庆医科大学附属第一医院肿瘤科
- 作者简介：
- 基金信息：
- DOI：
  CLC： R737.9
- Published：2011，
扫描看全文
[1]饶明月,张幸平,程丽,周涛琪,杨敏,何阳科.小剂量紫杉醇联合重组人血管内皮抑素对乳腺癌MCF-7细胞抑制作用的实验研究[J].重庆医科大学学报,2011,36(11):1335-1338.

RAO Ming-yue, ZHANG Xing-ping, CHENG Li, et al. Inhibitory effect of low-dose paclitaxel combined with recombinant human endostatin on breast cancer MCF-7 cell line. [J]. Journal of Chongqing Medical University 36(11):1335-1338(2011)
[1]饶明月,张幸平,程丽,周涛琪,杨敏,何阳科.小剂量紫杉醇联合重组人血管内皮抑素对乳腺癌MCF-7细胞抑制作用的实验研究[J].重庆医科大学学报,2011,36(11):1335-1338. DOI：

RAO Ming-yue, ZHANG Xing-ping, CHENG Li, et al. Inhibitory effect of low-dose paclitaxel combined with recombinant human endostatin on breast cancer MCF-7 cell line. [J]. Journal of Chongqing Medical University 36(11):1335-1338(2011) DOI：

摘要

目的:观察小剂量（40μg/ml）紫杉醇（Paclitaxel

PTX）联合重组人血管内皮抑素（Recombinant human endostatin

rh-ES）对人乳腺癌MCF-7细胞生长及其血管内皮生长因子（Vascular endothelial growth factor

VEGF）表达的抑制作用。方法:实验分为对照组（A组）、PTX组（B组）、rh-ES组（C组）及PTX+rh-ES组（D组）。用细胞计数板计数法测定各组药物作用于MCF-7细胞24 h后的细胞存活数并计算细胞抑制率。免疫细胞化学SABC法检测各组VEGF蛋白表达

RT-PCR法检测各组VEGFmRNA表达。结果:D组的细胞抑制率明显高于C组（P=0.002）

但与B组比较无统计学差异（P=0.57）。D组的VEGF蛋白及mRNA的表达较其余3组明显减少

差异具有统计学意义（P<0.05）。细胞抑制率的增加与VEGF表达减少之间具有线性相关性（r=0.564

P<0.001）。结论:小剂量PTX与rh-ES联合应用可明显抑制乳腺癌MCF-7细胞生长及其VEGF表达

提示两者联用在抑制肿瘤血管生成方面具有协同作用。

Abstract

Objective:To observe the low-dose(40 μg/ml) paclitaxel(PTX) combined with recombinant human endostatin(rh-ES) in inhibiting the growth of human breast cancer MCF-7 cell line and suppressing the gene expression of vascular endothelial growth factor(VEGF).Methods:The experiment had four groups:control group(group A)

group PTX(group B)

group rh-ES(group C) and group PTX + rh-ES(group D).It enumerated the surviving MCF-7 cells after 24 h

which were treated with the four methods.Inhibitory rate of cells of the four groups was calculated.The VEGF protein and mRNA expressions were detected by immunocytochemistry and RT-PCR.Results:The inhibitory rate of group D was higher than that of group C(P=0.002)

but there was no statistic significance of inhibitory rate between group D and group B(P=0.57).When VEGF protein and mRNA expressions were compared between each group

those in group D were significantly lower than in the other three groups(P<0.05).The increased inhibitory rate of MCF-7 cells and the decreased expression of VEGF were in linear correlation(r=0.564

P<0.001).Conclusion:Low-dose PTX combined with rh-ES can obviously inhibit the growth of MCF-7 cell line and suppress gene expression of VEGF.Our results demonstrate the combined use of low-dose PTX and rh-ES has synergistic effects in inhibiting tumor growth and angiogenesis.

关键词

乳腺癌紫杉醇抗血管生成化疗重组人血管内皮抑素血管内皮生长因子

Keywords

breast cancerpaclitaxelantiangiogenic chemotherapyrecombinant human endostatinVEGF

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Experimental study of recombinant human endostatin combined with NVB-Cisplatin on human breast cancer xenografts in nude mice

Study on the growth inhibition effect of Cetuximab combined with Paclitaxel on human breast cancer cell line MCF-7

Pathomics signature based on machine learning can predict the response to neoadjuvant chemotherapy in breast cancer patients

Effects of circular RNA hsa_circ_0002185 on cell viability and invasion of breast cancer cells and its mechanism of action

Prediction and identification of H-2Kd restricted CTL epitope derived from breast cancer associated antigen ROR1

Related Author

CHENG Li1

ZHANG Xing-ping1

YANG Hong-jie2

ZHOU Tao-qi1

RAO Ming-yue1

YANG Min

ZHANG Xingping

CHENG Li

Related Institution

Department of Oncology,the First Affiliated Hospital,Chongqing Medical University

Department of Morphology,School of Basic Medical Schence,Chengdu Medical College

(Department of Oncology, the First Affiliated Hospital, Chongqing Medical University)

Department of Epidemiology and Health Statistics， School of Public Health，Southwest Medical University

Department of Pathology，The Affiliated Hospital of Southwest Medical University

⁰